and basal cell carcinoma (BCC), cutaneous squamous cell carcinoma (cSCC), due to chronic immunosuppression., Immunosuppressed patients with premalignant and malignant skin lesions, such as actinic keratosis (AK)
Conditions
Brief summary
The complete clearance rate of lesions at 3 months, defined as the complete clinical disappearance of the treated lesion.
Detailed description
Reduction in the AKASI index: analyzed using an independent samples Student’s t-test or the Mann–Whitney U test depending on distribution., Recurrence or persistence at 6–12 months: analyzed using χ²/Fisher’s exact test., ncidence of new actinic keratoses (AK) or non-melanoma skin cancer (NMSC): comparison of proportions between groups.
Interventions
DRUGAmeluz 78 mg/g gel
Sponsors
Dra. Elena González Guerra
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The complete clearance rate of lesions at 3 months, defined as the complete clinical disappearance of the treated lesion. | — |
Secondary
| Measure | Time frame |
|---|---|
| Reduction in the AKASI index: analyzed using an independent samples Student’s t-test or the Mann–Whitney U test depending on distribution., Recurrence or persistence at 6–12 months: analyzed using χ²/Fisher’s exact test., ncidence of new actinic keratoses (AK) or non-melanoma skin cancer (NMSC): comparison of proportions between groups. | — |
Outcome results
None listed